A pilot study to assess whether glucagon-like Peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans.

Register
Cart (0)

Home > References > 2011 > A pilot study to assess whether glucagon-like Peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans.

Contact an Account Manager

A pilot study to assess whether glucagon-like Peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans.

Read, P.A., Hoole, S.P., White, P.A., Khan, F.Z., O'Sullivan, M., West, N.E., Dutka, D.P.

Journal		Circ Cardiovasc Interv.
Species
Analytes Measured		GLP-1
Matrix Tested		Plasma

Year		2011
Volume		4
Page Numbers		266-72
Application		Metabolic

Abstract

BACKGROUND: The incretin hormone glucagon-like peptide-1 (GLP-1) has been shown to have cardioprotective properties in animal models of ischemia and infarction due to promotion of myocardial glucose uptake and suppression of apoptosis. We investigated whether GLP-1 protected the heart from dysfunction caused by supply ischemia during percutaneous coronary intervention (PCI).

METHODS AND RESULTS: Twenty patients with normal left ventricular (LV) function and single-vessel coronary disease within the left anterior descending artery undergoing elective PCI were studied. A conductance catheter was placed into the LV through the femoral artery, and pressure-volume loops were recorded at baseline and during a 1-minute low-pressure balloon occlusion at the site of the stenosis. The patients were randomized to receive an infusion of either GLP-1(7-36) amide at 1.2 pmol/kg per minute or saline immediately after the first balloon occlusion. Coronary balloon occlusion caused LV stunning in the control group with cumulative LV dysfunction on subsequent occlusion that was not seen in the GLP-1 group. GLP-1 improved recovery of LV systolic and diastolic function at 30 minutes after balloon occlusion compared with control (delta dP/dt(max) from baseline, -1.6% versus -12.2%; P=0.02) and reduced the LV dysfunction after the second balloon occlusion (delta dP/dt(max), -13.1% versus -25.3%; P=0.01).

CONCLUSIONS: In this pilot study, infusion of GLP-1 has been demonstrated to reduce ischemic LV dysfunction after supply ischemia during coronary balloon occlusion in humans and mitigates stunning. The findings require confirmation in a larger scale clinical trial. CLINICAL TRIAL REGISTRATION: URL: http://www.isrctn.org. Unique identifier: ISRCTN 77442023.

View Publications

Related Products


U-PLEX Diabetes Combo 1 (mouse) C-Peptide, GLP-1 (total), Glucagon, Insulin, Leptin, PYY (total) \| Mouse Multiplex
U-PLEX Metabolic 3-Plex Combo 1 (mouse) GLP-1 (total), Glucagon, Insulin \| Mouse Multiplex
U-PLEX Microbiome Combo 1 (human) Ghrelin (total), GLP-1 (total), Glucagon, Insulin, Leptin, PP, PYY (total) \| Human Multiplex
U-PLEX Diabetes Combo 1 (rat) C-Peptide, GLP-1 (total), Glucagon, Insulin, Leptin, PYY (total) \| Rat Multiplex
U-PLEX Metabolic 3-Plex Combo 1 (rat) GLP-1 (total), Glucagon, Insulin \| Rat Multiplex
U-PLEX Diabetes Combo 1 (human) C-Peptide, GIP (total), GLP-1 (total), Glucagon, Insulin, Leptin, PYY (total) \| Human Multiplex
U-PLEX Custom Metabolic Group 1 (rat) 384-well Assays Rat Multiplex
U-PLEX Mouse GLP-1 (total) 384-Well Assay GLP-1 (total) \| Mouse Singleplex
U-PLEX Rat GLP-1 (total) 384-Well Assay GLP-1 (total) \| Rat Singleplex
U-PLEX Custom Metabolic Group 1 (mouse) 384-well Assays BAFF, BCA-1/BLC, BDNF, CD40/TNFRSF5, C-Peptide, Eotaxin, EPO, FGF-21, Ghrelin (active), Ghrelin (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, GM-CSF, IFN-α, IFN-β, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17E/IL-25, IL-17F, IL-21, IL-22, IL-23, IL-27p28/IL-30, IL-31, IL-33, Insulin, IP-10, KC/GRO, Leptin, MCP-1, MCP-5/CCL12, MDC, MIP-1α, MIP-1β, MIP-2, MIP-3α, MMP-9 (total), PYY (total), RANTES, TARC, TNF-α, VEGF-A \| Mouse Multiplex
U-PLEX Human GLP-1 (total) 384-well Assay GLP-1 (total) \| Human Singleplex
U-PLEX Custom Metabolic Group 1 (human) 384-well Assays BAFF, BDNF, β-NGF, C-Peptide, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, FGF-21, FGF-23, FLT3L, Fractalkine, FSH, G-CSF, Ghrelin (active), Ghrelin (total), GIP (active), GIP (inactive), GIP (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, GM-CSF, GRO-α, I-309, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, Insulin, IP-10, Leptin, Luteinizing Hormone (LH), MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1α, MIP-5, PP, Proinsulin, PYY (total), SDF-1α, TARC, TNF-α, TNF-β, TPO, TRAIL, TSLP, VEGF-A, YKL-40 \| Human Multiplex
U-PLEX Mouse GLP-1 (total) Assay GLP-1 (total) \| Mouse Singleplex
U-PLEX Rat GLP-1 (total) Assay GLP-1 (total) \| Rat Singleplex
U-PLEX Human GLP-1 (total) Assay GLP-1 (total) \| Human Singleplex
U-PLEX Custom Metabolic Group 1 (rat) Assays Rat Multiplex
U-PLEX Custom Metabolic Group 1 (mouse) Assays Mouse Multiplex
U-PLEX Obesity Combo 2 (rat) C-Peptide, Ghrelin (total), GLP-1 (total), Insulin, Leptin, PYY (total) \| Rat Multiplex
U-PLEX Obesity Combo 2 (mouse) C-Peptide, Ghrelin (total), GLP-1 (total), Insulin, Leptin, PYY (total) \| Mouse Multiplex
U-PLEX Metabolic Combo 1 (rat) BDNF, C-Peptide, FGF-21, Ghrelin (active), Ghrelin (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, Insulin, Leptin, PYY (total) \| Rat Multiplex
U-PLEX Metabolic Combo 1 (mouse) BAFF, BDNF, C-Peptide, FGF-21, Ghrelin (active), Ghrelin (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, Insulin, Leptin, PYY (total) \| Mouse Multiplex
U-PLEX Custom Metabolic Group 1 (human) Assays BAFF, BDNF, β-NGF, C-Peptide, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, FGF-21, FGF-23, FLT3L, Fractalkine, FSH, G-CSF, Ghrelin (active), Ghrelin (total), GIP (active), GIP (inactive), GIP (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, GM-CSF, GRO-α, I-309, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, Insulin, IP-10, Leptin, Luteinizing Hormone (LH), MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1α, MIP-5, PP, Proinsulin, PYY (total), SDF-1α, TARC, TNF-α, TNF-β, TPO, TRAIL, TSLP, VEGF-A, YKL-40 \| Human Multiplex
U-PLEX GLP-1 (total) Antibody Set (5 Plate Size) GLP-1 (total) \| Human, Mouse, Rat
U-PLEX Metabolic Combo 1 (human) BAFF, BDNF, β-NGF, C-Peptide, FGF-21, FGF-23, FSH, Ghrelin (active), Ghrelin (total), GIP (active), GIP (inactive), GIP (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, Insulin, Leptin, Luteinizing Hormone (LH), PP, Proinsulin, PYY (total) \| Human Multiplex
U-PLEX Obesity Combo 2 (human) C-Peptide, FGF-23, Ghrelin (total), GLP-1 (total), Insulin, Leptin, PYY (total) \| Human Multiplex
V-PLEX GLP-1 (total) Kit GLP-1 (total) \| Human, Mouse, Non-human primate, Rat, Canine Singleplex
V-PLEX Plus GLP-1 (total) Kit GLP-1 (total) \| Human, Mouse, Non-human primate, Rat, Canine Singleplex
GLP-1 (total) Control Pack GLP-1 (total) \| Human, Mouse, Non-human primate, Rat, Canine
GLP-1 (total) Antibody GLP-1 (total) \| Human

R-PLEX: Matched Antibody Sets - Suitable for Many Research Applications

Quick Links

Browse Our Products

By Analytes

By Applications

Contact Information

Customer Service/Orders
1-240-314-2795

5:00 a.m. to 8:00 p.m.
US Eastern Time

Email

Scientific/Technical Support
1-240-314-2798

5:30 a.m. to 5:30 p.m.
US Eastern Time

Email

Instrument Support
1-301-947-2057

8:30 a.m. - 5:30 p.m.
US Eastern Time

Email

Company Headquarters
1-240-314-2600
1601 Research Blvd.
Rockville, Maryland 20850-3173
USA


U-PLEX Diabetes Combo 1 (mouse) C-Peptide, GLP-1 (total), Glucagon, Insulin, Leptin, PYY (total) \| Mouse Multiplex
U-PLEX Metabolic 3-Plex Combo 1 (mouse) GLP-1 (total), Glucagon, Insulin \| Mouse Multiplex
U-PLEX Microbiome Combo 1 (human) Ghrelin (total), GLP-1 (total), Glucagon, Insulin, Leptin, PP, PYY (total) \| Human Multiplex
U-PLEX Diabetes Combo 1 (rat) C-Peptide, GLP-1 (total), Glucagon, Insulin, Leptin, PYY (total) \| Rat Multiplex
U-PLEX Metabolic 3-Plex Combo 1 (rat) GLP-1 (total), Glucagon, Insulin \| Rat Multiplex
U-PLEX Diabetes Combo 1 (human) C-Peptide, GIP (total), GLP-1 (total), Glucagon, Insulin, Leptin, PYY (total) \| Human Multiplex
U-PLEX Custom Metabolic Group 1 (rat) 384-well Assays Rat Multiplex
U-PLEX Mouse GLP-1 (total) 384-Well Assay GLP-1 (total) \| Mouse Singleplex
U-PLEX Rat GLP-1 (total) 384-Well Assay GLP-1 (total) \| Rat Singleplex
U-PLEX Custom Metabolic Group 1 (mouse) 384-well Assays BAFF, BCA-1/BLC, BDNF, CD40/TNFRSF5, C-Peptide, Eotaxin, EPO, FGF-21, Ghrelin (active), Ghrelin (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, GM-CSF, IFN-α, IFN-β, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17E/IL-25, IL-17F, IL-21, IL-22, IL-23, IL-27p28/IL-30, IL-31, IL-33, Insulin, IP-10, KC/GRO, Leptin, MCP-1, MCP-5/CCL12, MDC, MIP-1α, MIP-1β, MIP-2, MIP-3α, MMP-9 (total), PYY (total), RANTES, TARC, TNF-α, VEGF-A \| Mouse Multiplex
U-PLEX Human GLP-1 (total) 384-well Assay GLP-1 (total) \| Human Singleplex
U-PLEX Custom Metabolic Group 1 (human) 384-well Assays BAFF, BDNF, β-NGF, C-Peptide, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, FGF-21, FGF-23, FLT3L, Fractalkine, FSH, G-CSF, Ghrelin (active), Ghrelin (total), GIP (active), GIP (inactive), GIP (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, GM-CSF, GRO-α, I-309, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, Insulin, IP-10, Leptin, Luteinizing Hormone (LH), MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1α, MIP-5, PP, Proinsulin, PYY (total), SDF-1α, TARC, TNF-α, TNF-β, TPO, TRAIL, TSLP, VEGF-A, YKL-40 \| Human Multiplex
U-PLEX Mouse GLP-1 (total) Assay GLP-1 (total) \| Mouse Singleplex
U-PLEX Rat GLP-1 (total) Assay GLP-1 (total) \| Rat Singleplex
U-PLEX Human GLP-1 (total) Assay GLP-1 (total) \| Human Singleplex
U-PLEX Custom Metabolic Group 1 (rat) Assays Rat Multiplex
U-PLEX Custom Metabolic Group 1 (mouse) Assays Mouse Multiplex
U-PLEX Obesity Combo 2 (rat) C-Peptide, Ghrelin (total), GLP-1 (total), Insulin, Leptin, PYY (total) \| Rat Multiplex
U-PLEX Obesity Combo 2 (mouse) C-Peptide, Ghrelin (total), GLP-1 (total), Insulin, Leptin, PYY (total) \| Mouse Multiplex
U-PLEX Metabolic Combo 1 (rat) BDNF, C-Peptide, FGF-21, Ghrelin (active), Ghrelin (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, Insulin, Leptin, PYY (total) \| Rat Multiplex
U-PLEX Metabolic Combo 1 (mouse) BAFF, BDNF, C-Peptide, FGF-21, Ghrelin (active), Ghrelin (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, Insulin, Leptin, PYY (total) \| Mouse Multiplex
U-PLEX Custom Metabolic Group 1 (human) Assays BAFF, BDNF, β-NGF, C-Peptide, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, FGF-21, FGF-23, FLT3L, Fractalkine, FSH, G-CSF, Ghrelin (active), Ghrelin (total), GIP (active), GIP (inactive), GIP (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, GM-CSF, GRO-α, I-309, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, Insulin, IP-10, Leptin, Luteinizing Hormone (LH), MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1α, MIP-5, PP, Proinsulin, PYY (total), SDF-1α, TARC, TNF-α, TNF-β, TPO, TRAIL, TSLP, VEGF-A, YKL-40 \| Human Multiplex
U-PLEX GLP-1 (total) Antibody Set (5 Plate Size) GLP-1 (total) \| Human, Mouse, Rat
U-PLEX Metabolic Combo 1 (human) BAFF, BDNF, β-NGF, C-Peptide, FGF-21, FGF-23, FSH, Ghrelin (active), Ghrelin (total), GIP (active), GIP (inactive), GIP (total), GLP-1 (active), GLP-1 (inactive), GLP-1 (total), Glucagon, Insulin, Leptin, Luteinizing Hormone (LH), PP, Proinsulin, PYY (total) \| Human Multiplex
U-PLEX Obesity Combo 2 (human) C-Peptide, FGF-23, Ghrelin (total), GLP-1 (total), Insulin, Leptin, PYY (total) \| Human Multiplex
V-PLEX GLP-1 (total) Kit GLP-1 (total) \| Human, Mouse, Non-human primate, Rat, Canine Singleplex
V-PLEX Plus GLP-1 (total) Kit GLP-1 (total) \| Human, Mouse, Non-human primate, Rat, Canine Singleplex
GLP-1 (total) Control Pack GLP-1 (total) \| Human, Mouse, Non-human primate, Rat, Canine
GLP-1 (total) Antibody GLP-1 (total) \| Human

Please Sign In

User name

Password

A pilot study to assess whether glucagon-like Peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans.

Abstract

Related Products

Quick Links

Browse Our Products

Contact Information

Products

Services

Orders & Support

Key Topics